Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niggli

Showing results (481-490 of 516) with videos related to

Pageof 52
Sort By:
British Journal of Haematology|January 14, 2010
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapyHerbert Pichler, Anja Möricke, Georg Mann, et al.
Klinische Padiatrie|June 4, 2004
Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms TumorH Reinhard, O Semler, D Bürger, et al.
Nature Medicine|August 30, 2008
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic miceMilena Traykova-Brauch, Kai Schönig, Oliver Greiner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
The Lancet. Child & Adolescent Health|June 5, 2020
39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trialChrista Koenig, Nicole Bodmer, Philipp K A Agyeman, et al.
Leukemia|December 17, 2009
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000A Möricke, M Zimmermann, A Reiter, et al.
Nature Communications|September 16, 2020
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivityGabriele Manzella, Leonie D Schreck, Willemijn B Breunis, et al.
Haematologica|April 6, 2023
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemiaJanina Heilmann, Simon Vieth, Anja Möricke, et al.
Frontiers in Oncology|May 27, 2022
No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care TherapySebastian Johannes Schober, Erika Hallmen, Florian Reßle, et al.
Pageof 52

Showing results (481-490 of 516) with videos related to

Sort By:
Pageof 52
British Journal of Haematology|January 14, 2010
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapyHerbert Pichler, Anja Möricke, Georg Mann, et al.
Klinische Padiatrie|June 4, 2004
Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms TumorH Reinhard, O Semler, D Bürger, et al.
Nature Medicine|August 30, 2008
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic miceMilena Traykova-Brauch, Kai Schönig, Oliver Greiner, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studiesMark W Skinner, Claude Négrier, Ido Paz-Priel, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
The Lancet. Child & Adolescent Health|June 5, 2020
39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trialChrista Koenig, Nicole Bodmer, Philipp K A Agyeman, et al.
Leukemia|December 17, 2009
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000A Möricke, M Zimmermann, A Reiter, et al.
Nature Communications|September 16, 2020
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivityGabriele Manzella, Leonie D Schreck, Willemijn B Breunis, et al.
Haematologica|April 6, 2023
Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemiaJanina Heilmann, Simon Vieth, Anja Möricke, et al.
Frontiers in Oncology|May 27, 2022
No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care TherapySebastian Johannes Schober, Erika Hallmen, Florian Reßle, et al.
Pageof 52